Immunomodulation mixture and application

Abstract

The invention discloses an immunomodulation mixture which is prepared by decocting the following medicines with water: 30g radix astragali preparata, 10g ginseng, 15g bighead atractylodes rhizome, 15gturtle shell, 30g glossy privet fruit, 12g Chinese angelica, 12g radix paeoniae rubra, 12g cortex moutan, 15g radix rehmanniae recen, 6g radix sophorae flavescentis, 10g dock root and 6g radix glycyrrhizae preparata. The prepared immunomodulation mixture is used for a combination medicine for treating a congenital and acquired hemophilia inhibitor and administrated in two stages, namely remissioninduction (28 days) and consolidation therapy; the combination medicine is used for treating 26 patients with the congenital and acquired hemophilia inhibitor; and reexamination after treatment for 28 days shows that a complete remission rate is 96.15%, a partial remission rate is 3.85%, and a total effective rate is 100%. After follow-up for 1-3 years, only one patient experiences recurrence; the other 25 patients are alleviated continuously; the medical cost burden of the patients and the country can be reduced greatly; and a new medication is provided for treating the congenital and acquired hemophilia inhibitor.

Description

technical field [0001] The invention relates to a medicine for treating hemophilia, in particular to an immunoregulatory mixture and its application. Background technique [0002] Hemophilia (Hemophilia) is a group of bleeding disorders that are the most common among genetic diseases, and its clinical manifestations are characterized by three highs (high bleeding rate, high mortality rate, and high disability rate) [1-2] . For half a century, modern medicine has made great progress in the treatment of hemophilia hemorrhage with the replacement therapy of coagulation factor VIII / IX (FVIII / FIX). FIX homologous and self-specific inhibitors (FⅧ / FIX antibodies) are produced, inhibiting and inactivating 98% of FⅧ / FIX activity (FⅧ / FIX: C), resulting in ineffective coagulation factor replacement therapy, aggravating bleeding, death and disability Rate [3-4] . The production of inhibitors is the main reason for the ineffectiveness of current alternative therapies, and it is a wor...

AI Technical Summary

Problems solved by technology

The average success rate of antibody clearance is 70% for HA and 25% for HB, and can be complicated by allergic reactions and irreversible kidney damage. The recurrence rates in 1 year, 3 years, and 5 years are 12.8% and 32.5%, respectively, indicating that ITI therapy still has many defects

As far as blood sources are concerned, there are about 80,000 to 100,000 hemophiliacs in the country, and the concomitant rate of inhibitors is 20 to 30%. About 18 million tubes of human coagulation factor VIII are needed every year, which requires a huge amount of blood and funds, which is not conducive to saving blood sources and Medical expenses

[0004] For the treatment of acquired hemophilia complicated with inhibitors, prednisone 1-1.5 mg (kg.d) is the first choice at present, and cyclophosphamide 1-2 mg / (kg.d) and azathioprine 100 mg / d can be combined for treatment ineffective ~200mg / d, cyclosporine 2mg / (kg.d)~5mg / (kg.d), the course of treatment is 3~12 weeks, and the effective rate is 50%. Obesity, femoral head necrosis and other eight major side effects

Easy to relapse after drug withdrawal also brings difficulties to treatment

Images